Italia markets closed

Sanofi (0A2V.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
49,56-0,51 (-1,02%)
Alla chiusura: 06:00PM GMT
Schermo intero
Chiusura precedente50,07
Aperto49,18
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno49,18 - 49,28
Intervallo di 52 settimane49,18 - 49,28
Volume0
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,46
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

    European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has granted marketing authorization for Enjaymo® (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chr

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares – October 2022

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

  • GlobeNewswire

    Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis

    Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularisIf approved, Dupixent would be the first and only targeted medicine specifically indicated for prurigo nodularis in the European Union Paris and Tarrytown, N.Y. November 11, 2022. The European Medicines Agency’s Commi